155 related articles for article (PubMed ID: 33994736)
1. Analysis of SET and MYND Domain-Containing Protein 3 (SMYD3) Expression in Gallbladder Cancer: a Pilot Study.
Chandra P; Dixit R; Pratap A; Mishra S; Mishra R; Shukla VK
Indian J Surg Oncol; 2021 Apr; 12(Suppl 1):111-117. PubMed ID: 33994736
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of the SMYD3 Promotes Proliferation, Migration, and Invasion of Pancreatic Cancer.
Zhu CL; Huang Q
Dig Dis Sci; 2020 Feb; 65(2):489-499. PubMed ID: 31441002
[TBL] [Abstract][Full Text] [Related]
3. SET and MYND domain containing protein 3 in cancer.
Huang L; Xu AM
Am J Transl Res; 2017; 9(1):1-14. PubMed ID: 28123630
[TBL] [Abstract][Full Text] [Related]
4. Novel insights into SMYD2 and SMYD3 inhibitors: from potential anti-tumoural therapy to a variety of new applications.
Rubio-Tomás T
Mol Biol Rep; 2021 Nov; 48(11):7499-7508. PubMed ID: 34510321
[TBL] [Abstract][Full Text] [Related]
5. SMYD3 overexpression was a risk factor in the biological behavior and prognosis of gastric carcinoma.
Liu Y; Luo X; Deng J; Pan Y; Zhang L; Liang H
Tumour Biol; 2015 Apr; 36(4):2685-94. PubMed ID: 25472580
[TBL] [Abstract][Full Text] [Related]
6. Histone methyltransferase SMYD3 promotes MRTF-A-mediated transactivation of MYL9 and migration of MCF-7 breast cancer cells.
Luo XG; Zhang CL; Zhao WW; Liu ZP; Liu L; Mu A; Guo S; Wang N; Zhou H; Zhang TC
Cancer Lett; 2014 Mar; 344(1):129-137. PubMed ID: 24189459
[TBL] [Abstract][Full Text] [Related]
7. Smyd3 open & closed lock mechanism for substrate recruitment: The hinge motion of C-terminal domain inferred from μ-second molecular dynamics simulations.
Chandramouli B; Silvestri V; Scarno M; Ottini L; Chillemi G
Biochim Biophys Acta; 2016 Jul; 1860(7):1466-74. PubMed ID: 27085704
[TBL] [Abstract][Full Text] [Related]
8. Histone methyltransferase SMYD3 regulates the expression of transcriptional factors during bovine oocyte maturation and early embryonic development.
Bai H; Li Y; Gao H; Dong Y; Han P; Yu H
Cytotechnology; 2016 Aug; 68(4):849-59. PubMed ID: 25563599
[TBL] [Abstract][Full Text] [Related]
9. Elevated Levels of SET and MYND Domain-Containing Protein 3 Are Correlated with Overexpression of Transforming Growth Factor-β1 in Gastric Cancer.
Liu H; Liu Y; Kong F; Xin W; Li X; Liang H; Jia Y
J Am Coll Surg; 2015 Aug; 221(2):579-90. PubMed ID: 26077602
[TBL] [Abstract][Full Text] [Related]
10. Effect of SMYD3 on the microRNA expression profile of MCF-7 breast cancer cells.
Chen D; Liu L; Luo X; Mu A; Yan L; Chen X; Wang L; Wang N; He H; Zhou H; Zhang T
Oncol Lett; 2017 Aug; 14(2):1831-1840. PubMed ID: 28789418
[TBL] [Abstract][Full Text] [Related]
11. SMYD3 overexpression indicates poor prognosis and promotes cell proliferation, migration and invasion in non‑small cell lung cancer.
Li J; Zhao L; Pan Y; Ma X; Liu L; Wang W; You W
Int J Oncol; 2020 Sep; 57(3):756-766. PubMed ID: 32705243
[TBL] [Abstract][Full Text] [Related]
12. Is MYND Domain-Mediated Assembly of SMYD3 Complexes Involved in Calcium Dependent Signaling?
Zhang Y; Li C; Yang Z
Front Mol Biosci; 2019; 6():121. PubMed ID: 31737645
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of SMYD3 and matrix metalloproteinase-9 are associated with poor prognosis of patients with gastric cancer.
Liu Y; Liu H; Luo X; Deng J; Pan Y; Liang H
Tumour Biol; 2015 Jun; 36(6):4377-86. PubMed ID: 25627005
[TBL] [Abstract][Full Text] [Related]
14. SMYD3 promotes hepatocellular carcinoma progression by methylating S1PR1 promoters.
Zhang H; Zheng Z; Zhang R; Yan Y; Peng Y; Ye H; Lin L; Xu J; Li W; Huang P
Cell Death Dis; 2021 Jul; 12(8):731. PubMed ID: 34301921
[TBL] [Abstract][Full Text] [Related]
15. The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMYD3.
Liu C; Fang X; Ge Z; Jalink M; Kyo S; Björkholm M; Gruber A; Sjöberg J; Xu D
Cancer Res; 2007 Mar; 67(6):2626-31. PubMed ID: 17363582
[TBL] [Abstract][Full Text] [Related]
16. ATM Signaling Pathway Is Implicated in the SMYD3-mediated Proliferation and Migration of Gastric Cancer Cells.
Wang L; Wang QT; Liu YP; Dong QQ; Hu HJ; Miao Z; Li S; Liu Y; Zhou H; Zhang TC; Ma WJ; Luo XG
J Gastric Cancer; 2017 Dec; 17(4):295-305. PubMed ID: 29302370
[TBL] [Abstract][Full Text] [Related]
17. Correlations of
Ma SJ; Liu YM; Zhang YL; Chen MW; Cao W
Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29089464
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of SMYD3 was associated with increased STAT3 activation in gastric cancer.
Liu Y; Deng J; Luo X; Pan Y; Zhang L; Zhang R; Liang H
Med Oncol; 2015 Jan; 32(1):404. PubMed ID: 25471787
[TBL] [Abstract][Full Text] [Related]
19. SMYD3 promotes colon adenocarcinoma (COAD) progression by mediating cell proliferation and apoptosis.
Yue FR; Wei ZB; Yan RZ; Guo QH; Liu B; Zhang JH; Li Z
Exp Ther Med; 2020 Nov; 20(5):11. PubMed ID: 32934676
[TBL] [Abstract][Full Text] [Related]
20. SET and MYND domain-containing protein 3 inhibits tumor cell sensitivity to cisplatin.
Wang L; Xu ML; Wang C; Dong QQ; Miao Z; Chen XY; Wang N; He HP; Zhang TC; Luo XG
Oncol Lett; 2020 May; 19(5):3469-3476. PubMed ID: 32269620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
